---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-081052"
form_type: "8-K"
ticker: "NEUP"
cik: "0001191070"
company_name: "Neuphoria Therapeutics Inc."
filed_at: "2026-07-23T22:37:29+00:00"
generated_at: "2026-07-24T10:05:53.612712+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Neuphoria Therapeutics to be acquired by Scancell Holdings in all-stock merger with CVRs

## Summary
- Neuphoria shareholders to receive Parent ADSs and contingent value rights; expected to own ~11.1% of combined company.
- Scancell shareholders to own ~64.9%; PIPE investors to own ~17.3% with $38.6M gross proceeds at $0.1205/ADS.
- Closing conditions include stockholder approvals, Nasdaq listing of Parent ADSs, and at least $75M in PIPE proceeds.
- CVRs entitle holders to 100% of net proceeds from Merck collaboration, Pfizer/KAT6 license, and R&D tax credit over 15 years.
- UK Placing of ~$12M and Retail Offer up to $3M also announced; not conditional on merger completion.

## SEC filing metadata
- accession: 0001213900-26-081052
- form_type: 8-K
- ticker: NEUP
- cik: 0001191070
- company_name: Neuphoria Therapeutics Inc.
- filed_at: 2026-07-23T22:37:29+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 5.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1191070/000121390026081052/0001213900-26-081052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1191070/000121390026081052/ea0298914-8k_neuphoria.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-081052
- JSON: https://secwatch.observer/filing/0001213900-26-081052.json
- Plain text: https://secwatch.observer/filing/0001213900-26-081052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.